May. 29 at 4:34 PM
$ZBIO $10.40 +1.17. DAC (dollar average cost)
$7.55 (2.4.25). EXIT
$14.00.
BRIEF: Today announced management’s presentation at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 1:25 p.m. ET.
note: Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.